Acadian Asset Management LLC Krystal Biotech, Inc. Transaction History

Acadian Asset Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 11, 2020	SELL	$35.02 - $65.64 $176,220 - $330,300	-5,032 Closed	0 $0
Q4 2019 Feb 06, 2020	SELL	$33.17 - $65.23 $262,739 - $516,686	-7,921 Reduced 61.15%	5,032 $279,000
Q3 2019 Nov 07, 2019	SELL	$34.72 - $51.3 $685,268 - $1.01 Million	-19,737 Reduced 60.38%	12,953 $450,000
Q2 2019 Aug 08, 2019	BUY	$27.2 - $41.2 $352,321 - $533,663	12,953 Added 65.63%	32,690 $1.32 Million
Q1 2019 May 09, 2019	SELL	$19.86 - $32.9 $16,305 - $27,010	-821 Reduced 3.99%	19,737 $649,000
Q3 2018 Oct 30, 2018	BUY	$14.43 - $21.0 $120,577 - $175,476	8,356 Added 68.48%	20,558 $361,000
Q2 2018 Jul 24, 2018	BUY	$8.99 - $15.26 $92,875 - $157,651	10,331 Added 552.16%	12,202 $182,000
Q1 2018 Apr 12, 2018	BUY	$8.61 - $11.74 $16,109 - $21,965	1,871 New	1,871 $19,000

266

25M

270K

172K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.52B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.